ErVimmune

ErVimmune, a biotechnology company, spin-off of Centre Léon Bérard (CLB) and Centre de Recherche en Cancérologie de Lyon (CRCL) (Lyon, France), incorporated in October 2019, targeting cold tumors, which do not respond to current immunotherapies, by developing the next generation of cancer vaccines and cell therapies. The uniqueness of the project lies in an agile and reliable methodology for identifying and selecting a new source of unconventional tumor epitopes. Our lead candidate, ErVac01, aims to treat advanced/metastatic triple-negative breast cancer capable of covering more than 88% of the North American and Asian populations, and over 95% of the European population. Preclinical data (in silico, in vitro, and in vivo) have been compiled and presented to the American (FDA) and European (EMA) regulatory agencies. In January 2024, we launched a Series A funding round of 10 million euros to finance this crucial clinical stage, a milestone of high added value for the company and for patients awaiting new therapeutic solutions. In November 2023, ErVimmune was selected by the European EIC Accelerator program, obtaining mixed funding of 14 million euros: 2.5 million euros in grants and 11.5 million euros in equity. Thanks to this excellence program, the European Investment Bank (EIB) invested 5 million euros in the Series A, and our historical investor, Seventure, committed 2 million euros.